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Summary.-Seventy-eight adult patients with acute leukaemia were classified
cytologically into 3 categories: acute lymphoblastic leukaemia (ALL), acute myelo-
genous leukaemia (AML) or acute undifferentiated leukaemia (AUL). The periodic
acid-Schiff stain was of little value in differentiating the 3 groups. The treatment
response in each group was different: 94o/ of patients with ALL (16/17) achieved
complete remission with prednisone, vincristine and other drugs in standard use in
childhood ALL; 590° of patients with AML (27/46) achieved complete remission with
cytosine arabinoside and daunorubicin (22 patients), or 6-thioguanine and cyclo-
phosphamide (2 patients), 6-thioguanine, cyclophosphamide and Adriamycin (1
patient), and cytosine and Adriamycin (1 patient); only 2 out of 14 patients (14°/)
with acute undifferentiated leukaemia achieved complete remission using cytosine
and daunorubicin after an initial trial of prednisone and vincristine had failed.
Prednisone and vincristine would seem to be of no value in acute undifferentiated
leukaemia. It would seem also that no benefit is obtained by classifying all patients
with acute leukaemia over 20 years of age as " adult acute leukaemia " and treating
them with the same polypharmaceutical regimen. The problems posed by each
disease are different and such a policy serves only to obscure them.
THE IMPORTANCE of making the dis-
tinction between acute lymphoblastic and
acute myelogenous leukaemia lies in their
different response to cytotoxic drugs, and
in consequence the different median sur-
vival. The most successful therapy for
the induction of remission in acute
myelogenous leukaemia is with regimens
that employ cytosine arabinoside, either
in combination with daunorubicin (Crow-
ther et al., 1970, 1973) or 6-mercaptopurine
(6MP) (Bailey et al., 1971), or 6-thio-
guanine (Clarkson, 1972). Only a small
proportion of patients with acute lympho-
blastic leukaemia fail to respond to
prednisone and vincristine therapy, at
least in children (Simone et al., 1972).
Some workers have found it impossible
to distinguish between acute lympho-
blastic and acute myelogenous leukaemias
in adults, and have adopted protocols
which include drugs that are effective in
the treatment of both diseases (Whitecar
et al., 1972). Notwithstanding this, Mathe
and his colleagues (Mathe, Bernard and
Meaume, 1959; Mathe et al., 1971) have
further subdivided acute myelogenous
and acute lymphoblastic leukaemia and
related the subsequent cytological
sub-groups to remission length and
survival.
Both these groups have found cyto-
chemistry unhelpful whereas other work-
ers have put great store in the results of
cytochemical tests (Hayhoe and Flemens,
1969; Schmalzl and Braunsteiner, 1971).
These apparent discrepancies prompted
us prospectively to study the relationship
of cytology and cytochemistry to response
to treatment in adult patients with
acute leukaemia admitted to this hospital
during the period 1969-73.
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PATIENTS AND METHODS
The cases reported are those of acute
leukaemia in patients aged 20 years or over
seen at this hospital betw-een 1969 and 1973.
The diagnosis was made on a pre-treatment
marrow aspirate stained with the conven-
tional May-Griinwald-Giemsa stain. Peri-
odic acid-Schiff (PAS) and Sudan black
stains were performed on the same pre-
treatment marrow- aspirates by standard
methods (Dacie and Lewis, 1970). The
principal feature of acute myelogenous
leukaemia was the presence of myeloid
differentiation (i.e. azurophilic granules) in
cells that were otherwise unequivocal blast
cells: in many instances these cells comprised
only a relatively small proportion (but more
than 50o) of the total number of blast cells
present; other features included a low
nuclear-cytoplasrnic ratio, Auer bodies, more
than 2 nucleoli and agranular polymorphs;
it should be emphasized, however, that
myeloid differentiation was the only criterion
we employed for distinguishing AML from
AUL and ALL. The salient features of
acute lymphoblastic leukaemia were a high
nuclear-cytoplasmic ratio without evidence
of myeloid differentiation, and less than 2
nucleoli. The blast cells of acute undiffer-
entiated leukaemia showed no evidence
of myeloid differentiation and had a low
nuclear-cytoplasmic ratio. fn addition, the
blast cells of many of the cases of AUL
were large irregular cells w-ith deeply staining
basophilic cytoplasm. These features are
shown in the accompanying illustrations
(Fig. 1, 2, 3). The bone marrow aspirates
were assessed morphologically and cyto-
ehemically before any treatment had been
given, by one of us, and 2 other haemat-
ologists at this hospital reviewed the slides
using the same criteria for classification: no
difference in interpretation was observed.
The age range for patients with ALL w-as
20-82 years, with a median of 34 years;
the age range of the patients with AML was
20-66 years with a median of 51 years; the
age range of the patients with AUL was
26-68 years with a median of 49 years.
Induction of remission in patients with
ALL was w-ith prednisone 40 mg/M2 daily
for 3 weeks, orally, and vincristine 1-5 mg/M2
weekly for 3 doses, intravenously. In 4
cases complete remission was not obtained
on these agents alone and other drugs -were
added-Adriamycin in one case, cytosine
arabinoside and daunorubicin in 2 cases, and
asparaginase, 6MP and daunorubicin in the
fourth case. Remission in some patients
with ALL treated initially at outside hospitals
was induced with a mixture of different
agents including prednisolone, vincristine,
6MP, methotrexate and asparaginase. The
first 28 patients with AMIL w-ere treated
initially with cytosine arabinoside 0 75 mg/kg
intravenously 8-hourly for 9 doses, followed
by daunorubicin 1-5 ing/kg intravenously
72 h after the last dose of cytosine arabinoside.
The courses wNere repeated with 5-day gaps
until remission ensued or until 6 courses
had been completed without success. In
the latter event treatment with 6-thioguanine
2-5 mg/kg orally daily and cyclophosphamide
200 mg/M2 orally weekly was substituted.
The last 18 patients with AML have been
treated with cytosine arabinoside 10 mg/kg
in 1 litre of normal saline by intravenous
infusion over 24 h. Daunorubicin 15 mg/kg
was given intravenously at the end of the
infusion. Patients who failed to remit on
this regimen were given cytosine in the same
manner, accompanied by Adriamycin 80
mg/M2 intravenously at the end of the
infusion (2 patients), 6-thioguanine and
cyclophosphainide in the manner described
above (1 patient), and 6-thioguanine, cyclo-
phosphamide and Adriamycin (1 patient).
Twelve of the 14 patients w'ith AUL were
treated initially with prednisone and vin-
cristine in the same dosage as used for
patients with ALL. If the blood blast cell
count w%as the same or higher at the end of
one week on this regimen, or if, in the
absence at presentation of blast cells in the
blood, a bone marrow- aspirate was not
improved at the end of one week, therapy
w-ith cytosine arabinoside and daunorubicin
was substituted. The 2 other patients were
treated w,ith the 24-h infusion regimen of
cytosine arabinoside and daunorubicin with-
out a prior trial of prednisone and vincristine.
A complete remission w-as considered to have
occurred when the patient became asympto-
matic, had no abnormal physical signs, and
when the blood count and marrow aspirate
had returned to normal. Maintenance regi-
mens for the patients with ALL varied, but
all consisted of agents in standard use for
ALL. Some of the regimens would be
considered inadequate by current standards,
and only 5 of the 16 patients in whom a
complete remission wAas obtained received
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FIa. I.-ALL: high nuclear cytoplasmic ratio, less than 2 nuclcoli and absence of any myeloidl
differentiation.
FIG. 2.-AML: 2 or more nucleoli. azurophilic granules, with myeloid differentiation.
FiG. 3.- AUL: low nuclear cytoplasmic ratio, one large nucleolus, and absence of any dlegree of
differentiation.ADULT ACUTE LEUKAEMIA
early prophylactic treatment to the central
nervous system. Of the patients with AML
obtaining complete remission (26), 6 Nere
given maintenance chemotherapy and 20
maintenance immunotherapy. The main-
tenance chemotherapy consisted of 6-thio-
guanine and cyclophosphamide given for
12 weeks, initially in the dosages quoted
previously, with a single course of
cytosine arabinoside and daunorubicin at
the end of each 12-week period.
Maintenance immunotherapy (Powles, 1973)
consisted of weekly subcutaneous injections
of irradiated allogeneic myeloid leukaemic
blast cells into 3 sites, together with Glaxo
B.C.G. into a fourth site.
RESULTS
The number of patients in each group
and their response to therapy are shown
in Table I. Thus, 16 of 17 adults with
acute lymphoblastic leukaemia obtained
complete remission (94%0). Four of 14
required the addition of either Adria-
mycin, cytosine or daunorubicin to the
standard induction drugs before com-
plete remission was obtained. The single
patient who did not achieve a complete
remission lhad severe, chronic obstructive
airways disease and died of staphylococcal
septicaemia when his marrow was hypo-
plastic due to chemotherapy.
Twenty-seven of 46 patients with
acute myelogenous leukaemia obtained
complete remission (5900). Twenty-three
of the 27 achieved remission with cytosine
arabinoside and daunorubicin (13/28 when
cytosine was given over 3 days, and 10/18
when it was given by 24-h infuision).
TABLE I. Response of
Complete remission
on P/V Complete remie
or P/MP on P/V/ADRIi
or P/V/MP or P/V/MP/CA
No. of or P/V/ASP or P/V/CA
Disease patients or P/V/MP/MITX or P/V/MP/AS:
ALL 17 12/12 4/5
AML 46 Not given Not given
AUL 14 0/12 Not given
* After failure on CA/DR.
ADRIA Adriamycin, CA cytosine arabinoside, TG
lone, V vincristine, MP 6-mercaptopurine, MTX met}
After failure with these 2 agents, 1 patient
obtained complete remission with 6-thio-
guanine and cyclophosphamide, 1 patient
with 6-thioguanine, cyclophosphamide and
Adriamycin, and 2 with cytosine and
Adriamycin. Prednisone and vincristine
were not used in this group.
Two patients out of 14 (14%) with
acute undifferentiated leukaemia achieved
complete remission. Twelve patients re-
ceived prednisone and vincristine first but
none obtained a complete remission with
these agents. Ten then received cytosine
arabinoside and daunorubicin, and 2
achieved a complete remission. Of the
remaining 8 who did not achieve a
remission on the latter 2 agents, 7 were
insensitive to the drugs; one died of a
gram-negative septicaemia before an ade-
quate trial could be giveni.
Life table analysis of the survival of
all patients included in this study is
shown in Fig. 4 and it can be seen that
patients with ALL fare much better
than the others. Predictive actuarial
analysis of these data gives a median
survival for the AUL patients of 3
months; the AML patients of 7 months
and ALL patients of 45 months. These
figures include patients who did not
achieve remission.
The results of cytochemical staining
with PAS and Sudan black stains are
shown in Table II. The blast cells of
only half the patients with ALL showed
PAS positivity as defined by Hayhoe,
Quaglino and Doll (1964), while the blast
cells of 5 of 13 patients with AUL also
showed PAS positivity. This was also
each Group to Therapy
ssion Complete
remission No. of patients
/DR Complete on TG/CY*, in whom no
remission CA/ADRIA*, remission was
P/DR on CA/DR or TG/CY/ADRTA* obtained
Not given Not given 1/17
23/46 4/19 19/46
2/10 0/4 12/14
6 thioguanine, CY cyclophosphamide, P predniso-
iotrexate, ASP asparaginase, DR daunorubicin.
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(AML)
ALL
Alive
A Dead
Time (months)
Fie. 4.-Patient survival.
TABLE II. Cytochemical Staining Char-
acteristics ofthe Three Groups
No. of patients Positive Positive
evaluated with PAS Sudan
Disease cytochemical stains stain black stain
ALL 16 8 0
AML 41 0 40
AUL 13 5 1
in the form of clumps of PAS positive
material, not merely diffuse staining of
the cytoplasm. The intracellular distri-
bution of the PAS positive material
noted had no diagnostic value. No pa-
tient with ALL showed Sudan black
positivity, but one patient with AUL
exhibited weak positivity. Positive Sudan
black stains were really the preserve of
patients with AML, all but one of whom
showed this feature. Four of the latter
group had fine granular PAS positivity
in a varying proportion of their blast
cells and in the absence of any monocytic
differentiation.
DlSCUSSION
In contrast to other workers (Whitecar
et al., 1972; Skeel et al., 1973) who have
not distinguished between acute lympho-
blastic leukaemia and acute myelogenous
leukaemia in adults, we have found it
relatively easy to do so and have also
separated off a further group acute
undifferentiated leukaemia. This cyto-
logical separation was vindicated by a
(A
4.
0.
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different response to treatment and a
different prognosis in each ofthe 3 groups.
The problems associated with each disease
are different, and protocols aimed indis-
criminately at covering all forms of adult
acute leukaemia serve only to obscure
those problems.
Sixteen of 17 patients (94%) with
classic ALL obtained complete remission;
although it is probable that the disease
is harder to control in adults than in
children (Jacquillat et al., 1973), the
main problem nevertheless is not one
of remission induction but of remission
maintenance. Unnecessarily heavy che-
motherapy at the time of remission
induction may simply exacerbate that
well recognized period of neutropenic
susceptibility to infection that sometimes
follows even therapy with prednisone and
vincristine in this disease (Hughes and
Smith, 1973) and lead to an unnecessary
fatality. We do, however, give prophy-
lactic therapy to the central nervous
system once marrow remission has been
obtained, and then use an intensive
maintenance regimen. Not only is the
complete remission rate much higher in
ALL than in the other 2 diseases, but the
predicted survival is longer.
Twenty-seven of 46 patients (59%)
with AML achieved complete remission.
Included in this group are patients with
the variant forms-acute myelocytic,
acute monomyelocytic and acute pro-
myelocytic leukaemia-which Mathe et
al. (1971) have shown to be associated
with a poor prognosis. We have re-
frained from separating these variants
off as no practical therapeutic advantage
is gained by doing so. In acute myelo-
genous leukaemia the main problem is
the relative ineffectiveness of the best
agents available cytosine arabinoside in
combination with daunorubicin, or 6-
thioguanine, or 6-mercaptopurine.
Only 2 of 14 patients with acute
undifferentiated leukaemia achieved com-
plete remission, and the problem in this
disease is the same as in AML but more
serious-the ineffectiveness of drugs used
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in attempting to induce remission. This
group is probably comprised of the acute
monoblastic and acute promyeloblastic
leukaemias described by Mathe et al.
(1971), which we were unable to separate.
As both are refractory to treatment and
have a very poor prognosis, no useful
function is performed by attempting to
do so. The median survival (3 months)
of our group of patients with AUL is
so poor that the ethics of treating this
group with aggressive chemotherapy in
hospital are, at the present moment, open
to question.
Although there were no cases in this
series with which we had difficulty with
the diagnosis prospectively, we have seen
2 cases subsequently in which we could
not distinguish between AUL and ALL.
In particular, the macrolymphoblastic
variant of ALL (Mathe et al., 1971) can
be confused with AUL when the nuclear-
cytoplasmic ratio of the latter is inter-
mediate. In this situation we give the
patient a therapeutic trial of prednisone
and vincristine, although it is no longer
our policy to use these 2 drugs routinely
for AUL.
Hayhoe et al. (1964) made the observa-
tion that coarse granules or blocks of
PAS positive material were infrequent
in the cytoplasm of primitive cells that
had Sudan black positivity, whereas they
were common in blast cells with negative
Sudan black reactions. Furthermore, 40
of 47 cases designated as acute lympho-
blastic leukaemia showed coarse PAS
positivity. This association, together
with the known PAS positivity of mature
lymphocytes, has allowed the presence of
PAS positive material in blast cells to
become synonymous with a diagnosis of
acute lymphoblastic leukaemia. How-
ever, no PAS positivity was noted in
50% of our adult patients with acute
lymphoblastic leukaemia, but was seen
in 5 of 13 patients with acute undiffer-
entiated leukaemia, so that the stain is
valueless as an indicator oflikely response
to prednisone and vincristine. Some
granular PAS positive material was seen
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in a proportion of blast cells (usually
less than 5%) in some cases of acute
myelogenous leukaemia. As PAS positi-
vity may be seen in the primitive cells
of blast cell transformation of chronic
myeloid leukaemia, it seems reasonable
to conclude that it is not the total preserve
of lymphoid cells. Its value is confined
to providing supporting evidence for the
diagnosis of erythroleukaemia in which
clumps of PAS positive material may be
seen in the abnormal erythroblasts. Sudan
black positivity was seen virtually only
in patients with cytological acute myelo-
genous leukaemia, and in our experience
is found infrequently in the absence of
myeloid differentiation discernible on rou-
tine May-Gruinwald-Giemsa staining.
It is not pretended that the proposed
classification, whose only criteria are the
presence of myeloid differentiation and
the nuclear-cytoplasmic ratio, solves all
the problems of the classification of
adult acute leukaemia. However, it has
the advantages of extreme simplicity,
definite chemotherapeutic implications
and prognostic value.
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